Arvinder Dhalla
Director, Biology Gilead Palo Alto, Inc.
CA 94304, USA
Dr. Arvinder Dhalla is currently the Director of Biology in Cardiovascular Therapeutic Area at Gilead Sciences and leads the CardioMetabolic group. She completed her PhD degree in cardiovascular physiology from St. Boniface Institute of Cardiovascular Sciences at University of Manitoba Canada in 1994. Arvinder did her postdoctoral training at the University of Missouri, Columbia. Arvinder worked as a scientist and senior scientist and project leader at CV Therapeutics from 2001-2008. Arvinder has published 40 papers in peer reviewed journals and has served as a reviewer for various journals. She is a member of several professional societies including American Heart Association and American Diabetes association
A1 adenosine receptor agonists as anti-lipolytic agents. Role of adipose tissue lipolysis and FFA in insulin resistance and diabetes. Role of Late Ina in ischemia and heart failure. Role of oxidative stress and anti-oxidants in transition of hypertrophy and heart failure. Role and regulation of extracellular matrix in hypertrophy and heart failure.
